PMID- 24785277
OWN - NLM
STAT- MEDLINE
DCOM- 20141108
LR  - 20141120
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 36
IP  - 3
DP  - 2014 Mar
TI  - [HER-2 overexpression and gene amplification of advanced breast cancers 
      determined by fluorescence in situ hybridization in fine needle aspiration 
      specimens].
PG  - 183-7
AB  - OBJECTIVE: To explore the feasibility of testing HER-2 expression and gene 
      amplification in fine needle aspiration specimens of advanced breast cancers, and 
      to benefit the patients receiving targeted drug therapy. METHODS: Liquid-based 
      cytology specimens by fine needle aspiration of 49 breast cancer cases were used 
      in this study. The expression of HER-2 protein was detected by 
      immunocytochemistry (ICC) and the gene amplification was assessed by fluorescence 
      in situ hybridization (FISH). All the 49 cases had overexpression of HER-2 
      protein marked as ++ or +++ in immunohistochemistry (IHC), and had corresponding 
      FISH results in formalin-fixed, paraffin-embedded (FFPE) tissue samples. RESULTS: 
      FNA samples in all the 49 cases were tested by FISH, and showed a complete 
      agreement with the FISH results in the histological specimens (kappa = 1.0). Of 
      the 49 cases, 33 had HER-2 gene amplification in FFPE samples. So do that in FNA 
      samples. Both had an amplification rate of 67.3%. Among the 33 cases with HER-2 
      gene amplification, 26 had an ICC score of +++ (78.8%). The conformity rate was 
      78.8%. Of the 33 cases, 29 had an IHC score of +++ (87.9%). Its conformity rate 
      was 87.9%. The difference between the ICC and IHC results was statistically not 
      significant (P = 0.322). Among the 16 cases with negative gene amplification by 
      both ICC and IHC, 15 cases showed HER-2 protein expression as 0/+, and another 
      one case was not counted because there was not enough cells. Of the 16 cases, 15 
      had an IHC score of ++ and one of +++ . To take the FISH results as gold 
      standard, ICC results had a high sensitivity (87.9%) and specificity (100.0%). 
      CONCLUSIONS: FISH in FNA samples can be used in the clinic to test HER-2 gene 
      amplification and overexpression in breast cancers, with a high sensitivity and 
      specificity in ICC. Our data support the use of FISH and ICC analysis to 
      determine HER-2 status on FNA specimens in patients with advanced breast cancer 
      and recurrence or metastatic tumors. When ICC score is +++ , it indicates that 
      there is a HER-2 gene amplification by FISH.
FAU - Zhang, Zhihui
AU  - Zhang Z
AD  - Department of Cytopathology, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
FAU - Zhao, Linlin
AU  - Zhao L
AD  - Department of Cytopathology, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
FAU - Guo, Huiqin
AU  - Guo H
AD  - Department of Cytopathology, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
FAU - Guo, Lei
AU  - Guo L
AD  - Department of Cytopathology, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
FAU - Ling, Yun
AU  - Ling Y
AD  - Department of Cytopathology, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
FAU - Xu, Xin
AU  - Xu X
AD  - Department of Cytopathology, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
FAU - Zhao, Huan
AU  - Zhao H
AD  - Department of Cytopathology, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
FAU - Pan, Qinjing
AU  - Pan Q
AD  - Department of Cytopathology, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China. Email: 
      pqjing@hotmail.com.
LA  - chi
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biopsy, Fine-Needle
MH  - *Breast Neoplasms/genetics/metabolism/pathology
MH  - *Carcinoma, Ductal, Breast/genetics/metabolism/pathology
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - Paraffin Embedding
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Sensitivity and Specificity
EDAT- 2014/05/03 06:00
MHDA- 2014/11/09 06:00
CRDT- 2014/05/03 06:00
PHST- 2014/05/03 06:00 [entrez]
PHST- 2014/05/03 06:00 [pubmed]
PHST- 2014/11/09 06:00 [medline]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2014 Mar;36(3):183-7.